Attention explores space periodically at the theta frequency

Voluntary attention is at the core of a wide variety of cognitive functions. Attention can be oriented to and sustained at a location or reoriented in space to allow processing at other locations—critical in an ever-changing environment. Numerous studies have investigated attentional orienting in time and space, but little is known about the spatiotemporal dynamics of attentional reorienting. Here we explicitly manipulated attentional reorienting using a cuing procedure in a two- alternative forced-choice orientation-discrimination task. We interrogated attentional distribution by flashing two probe stimuli with various delays between the precue and target stimuli. Then we used the probabilities that both probes and neither probe were correctly reported to solve a second-degree equation, which estimates the report probability at each probe location. We demonstrated that attention reorients periodically at ~4 Hz (theta) between the two stimulus locations. We further characterized the processing dynamics at each stimulus location, and demonstrated that attention samples each location periodically at ;11 Hz (alpha). Finally, simulations support our findings and show that this method is sufficiently powered, making it a valuable tool for studying the spatiotemporal dynamics of attention

Developing an evidence-based program sustainability training curriculum: A group randomized, multi-phase approach

Abstract Background The emergence of dissemination and implementation (D&I) science has driven a rapid increase in studies of how new scientific discoveries are translated and developed into evidence-based programs and policies. However, D&I science has paid much less attention to what happens to programs once they have been implemented. Public health programs can only deliver benefits if they reach maturity and sustain activities over time. In order to achieve the full benefits of significant investment in public health research and program development, there must be an understanding of the factors that relate to sustainability to inform development of tools and trainings to support strategic long-term program sustainability. Tobacco control programs, specifically, vary in their abilities to support and sustain themselves over time. As of 2018, most states still do not meet the CDC-recommended level for funding their TC program, allowing tobacco use to remain the leading cause of preventable disease and death in the USA. The purpose of this study is to empirically develop, test, and disseminate training programs to improve the sustainability of evidence-based state tobacco control programs and thus, tobacco-related health outcomes. Methods This paper describes the methods of a group randomized, multi-phase study that evaluates the empirically developed “Program Sustainability Action Planning Training” and technical assistance in US state-level tobacco control programs. Phase 1 includes developing the sustainability action planning training curriculum and technical assistance protocol and developing measures to assess long-term program sustainability. Phase 2 includes a group randomized trial to test the effectiveness of the training and technical assistance in improving sustainability outcomes in 24 state tobacco control programs (12 intervention, 12 comparison). Phase 3 includes the active dissemination of final training curricula materials to a broader public health audience. Discussion Empirical evidence has established that program sustainability can improve through training and technical assistance; however, to our knowledge, no evidence-based sustainability training curriculum program exists. Therefore, systematic methods are needed to develop, test, and disseminate a training that improves the sustainability of evidence-based programs. Trial registration NCT03598114. Registered 25 July 2018—retrospectively registered

Further Decoding the Molecular Relationship Between Pancreatic Ductal Adenocarcinoma and Diabetes Mellitus

Background: Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy, especially as there are no current reliable methods of screening. A significant relationship between PDAC and Diabetes Mellitus (DM), specifically a new onset of diabetes mellitus (NOD). The molecular network of PDAC and new onset DM is not completely understood. We sought to investigate the molecular network of these two diseases with the ultimate goal of identifying potential biomarkers to aid in the screening of PDAC. Methods: We conducted a review for relevant articles concerning the molecular relationship between PDAC and DM. We compiled a list of 74 genes which have been implicated in the relationship between PDAC and DM. These genes were used for the construction of gene interaction network (GIN) by using GeneMANIA on the bases of genetic interactions, co-expression, co-localization, pathway, physical interactions, predicted interaction and shared protein domains. The GIN input file was imported in the cytoscape for the pathways enrichment analyses by using KEGG plugin. The cytoscape was used for the construction of the final GIN of both normal and cancer genes separately. Results: GIN and pathways enrichment analyses of genes known to be altered during NOD/DM and PDAC indicate their association with different pathways. in this study we have mentioned around 20 enriched pathways in the associated tables and figures which promptly show the direct and indirect association with pancreatic cancer. The major signaling pathways that were observed to be upregulated include NABA Matrisome, protein phosphorylation, metabolic processes and proteins upregulated a s a result of hormone response. Out of all pathways, proteins that are more involved in metabolic processes were found most influenced. Conclusion: In conclusion, we have contributed to identifying the molecular network relating PDAC and DM. Our future aim is to investigate the genes associated in this pathway. We will use this data to design a panel for next generation sequencing in tissue samples of patients diagnosed with PDAC

A randomized, controlled trial of interferon-β-1a (Avonex(®)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]

The objective of this study was to evaluate the safety and possible efficacy of IFN-β-1a for the treatment of patients with rheumatoid arthritis (RA). Twenty-two patients with active RA were enrolled in a phase II randomized, double-blind, placebo-controlled trial of 30 μg IFN-β-1a by weekly self-injection for 24 weeks. The primary outcome of the study was safety. Secondary outcomes included the proportion of patients achieving an American College of Rheumatology (ACR) 20 response at 24 weeks. There were no significant differences in adverse events reported in the two groups. Fewer than 20% of patients in each arm of the study achieved an ACR 20 response at 24 weeks (P = 0.71). Sixty-nine percent of patients receiving IFN-β and 67% receiving placebo terminated the study early, most of them secondary to a perceived lack of efficacy. Overall, IFN-β-1a had a safety profile similar to that of placebo. There were no significant differences in the proportion of patients achieving an ACR 20 response between the two groups